Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and efficacy of BAY59-7939 with the safety
and efficacy of the licensed drug enoxaparin and a licensed oral vitamin K-antagonist and to
find the optimal dose of BAY59-7939 for the anticipated phase III trials and for the future
clinical use.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer
Treatments:
Enoxaparin Factor Xa Inhibitors Rivaroxaban Vitamin K Vitamins